Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China

2024

Characteristics of Patients with Non-Severe Infections of Different SARS-CoV-2 Omicron Subvariants in China

Sample size: 244 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yuan Wenfang, Liu Yongmei, Zhan Haoting, Wei Feng, Zhang Qian, Gao Huixia, Yan Huimin, Huang Tao, Li Yongzhe, Dai Erhei

Primary Institution: The Fifth Hospital of Shijiazhuang, Hebei Medical University

Hypothesis

The study aims to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease and evaluate the safety and efficacy of Azvudine for treatment of COVID-19.

Conclusion

The study demonstrated differences in clinical and laboratory parameters between patients infected with Omicron BA.2.76 and BA.5.1, as well as the safety and efficacy of Azvudine therapy.

Supporting Evidence

Patients infected with BA.5.1 exhibited a higher incidence of clinical symptoms like fatigue and headache compared to BA.2.76.
Azvudine treatment reduced the time for virus clearance compared to control treatment.
28.1% of patients reported mild adverse events following Azvudine administration.

Takeaway

This study looked at how different types of Omicron infections affect patients and found that a medicine called Azvudine helps them get better.

Methodology

A total of 244 individuals with Omicron subvariant (BA.2.76, n=158; BA.5.1, n=86) were included in the study, and demographic, clinical, and laboratory data were collected and analyzed.